Status:

COMPLETED

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Lead Sponsor:

Avid Radiopharmaceuticals

Conditions:

Dementia With Lewy Bodies

Alzheimer's Disease

Eligibility:

All Genders

50+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria DLB:
  • Male or female \> 50 years of age
  • Meet the diagnostic criteria for probable DLB as established by the DLB Consortium (McKeith et al., 2005)
  • Inclusion Criteria AD:
  • Male or female \> 50 years of age
  • Meet the NINCDS criteria for probable AD and have a Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive
  • Inclusion Criteria PD:
  • Male or female \> 50 years of age
  • Have probable PD according to the following criteria (Gelb et al., 1999):
  • Presence of 2 of the following 3 features: rest tremor, rigidity, bradykinesia;
  • Documented history of a sustained (\>6 months) improvement to Levodopa (L-DOPA) or a dopamine agonist
  • Absence of atypical clinical features or other possible signs or symptoms suggesting another cause of parkinsonism such as a history of frequent falls as a prominent early feature, localized brain lesion(s) or neuroleptic use
  • Asymmetric onset
  • A diagnosis of PD made within the 4 years prior to enrollment
  • Normal subjects:
  • Are males or females \> 50 years of age
  • Have a MMSE score \> 29, and are cognitively normal on the psychometric test battery at screening
  • Have no signs or symptoms of clinically meaningful parkinsonism
  • Exclusion Criteria:
  • Have a history or current diagnosis of other neurologic disease
  • Have evidence of clinically significant cerebrovascular disease
  • Have evidence from MRI or other biomarker studies that suggests the presence of a CNS pathology other than that associated with the study diseases

Exclusion

    Key Trial Info

    Start Date :

    March 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2011

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT01503944

    Start Date

    March 1 2010

    End Date

    July 1 2011

    Last Update

    August 14 2012

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Research Site

    Sun City, Arizona, United States

    2

    Research Site

    Philadelphia, Pennsylvania, United States